A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
← catalyst calendarSponsored by Turn Therapeutics (industry) · TTRX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
110estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-11 | actual | When the study began enrolling |
| Primary completion | 2026-07-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-10 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Eczema Atopic Dermatitis
- Eczema
- Atopic Dermatitis
Interventions
- Combination product: GX-03
- Other: Vehicle
Primary outcome
what the primary-completion date above is the date OFChange in Investigator Global Assessment (IGA) at Week 8
measured At Day 56 (Week 8)
Permalink · TTRX's whole pipeline · Catalyst calendar · Every registered study · What changed